|Bid||1,349.00 x 240300|
|Ask||1,358.00 x 53000|
|Day's Range||1,340.00 - 1,351.00|
|52 Week Range||1,064.91 - 1,351.00|
|PE Ratio (TTM)||15.39|
|Earnings Date||Jul 27, 2017|
|Dividend & Yield||0.31 (1.93%)|
|1y Target Est||17.04|
Smith & Nephew , the global medical technology business, proudly supports results of an independent, randomised clinical trial1 concluding that, in the patients studied, the use of the PICO Single Use Negative Pressure Wound Therapy system significantly reduced the rate of surgical site infections by 74%, compared to standard care in patients undergoing major abdominal incisions.
The chief executive of Smith & Nephew said on Friday that M&A was not at the top of his agenda, as the focus was on driving growth at the artificial knee and hip maker. A report in the Financial Times in March said Wright Medical , a U.S. company that specialise in surgical implants for extremities like feet and ankles, could be a takeover target for the British company. S&N Chief Executive Olivier Bohuon said M&A was "always on the agenda", and he had previously pointed to extremities as one of a number of areas of interest.
Let's take a look at the major Medical products stocks slated to release their first-quarter 2017 reports on May 5.